Billion-dollar bio-based chemicals IPO window is open, as Solazyme IPOs and Myriant files

June 02, 2011 | Analyst Insight

Solazyme's much-anticipated initial public offering (IPO) finally happened last Friday, selling about 11 million shares at $18 – raising $198 million in total, twice what it expected when it filed (see...

About Lux Research

Lux Research is a leading provider of tech-enabled research and advisory solutions, helping clients drive growth through technology innovation. A pioneer in the research industry, Lux uniquely combines technical expertise and business insights with a proprietary intelligence platform, using advanced analytics and data science to surface true leading indicators. With quality data derived from primary research, fact-based analysis, and opinions that challenge traditional thinking, Lux clients are empowered to make more informed decisions today to ensure future success.

Already a Lux Client?

Sign In

Interested in Learning More?

Contact us to learn the benefits of becoming a Lux member.

Or call us now

For North America (Boston Headquarters)
+1 (617) 502-5300

For EMEA (Amsterdam)
+31 20 280 7900

For APAC (Singapore)
+65 6592-6978

© 2004-2021 Lux Research, Inc. All Lux Research content is intended only for consumption by Lux Research clients; redistribution is prohibited and copyright is strictly enforced. All material is based on information obtained from sources believed to be reliable but no independent verification has been made, nor is its accuracy or completeness guaranteed. All material is published solely for informational purposes and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments.